It was great to bring everyone together and also welcome new member John Parkinson."

September 2022 "Parkinson’s disease (PD) as a progressive neurodegenerative disorder arises from multiple

April 2022 John Streicher talks about his work on terpenes found in cannabis as these may be a novel way to treat pain without the negative side effects "Many people are familiar with cannabis, but John

Join the #GPCR movement by becoming a site member for FREE!

Join us now ➡️ https://www.ecosystem.drgpcr.com/dr-gpcr-summit-2022 #gpcr #drgpcr

Boston, MA and San Diego, CA — [February 18, 2026] — Dr. GPCR , the global knowledge hub for G protein-coupled receptor (GPCR) research and education, today announced a strategic partnership with Eurofins DiscoverX , a global leader in GPCR product solutions including cell-based assay product solutions supporting drug discovery, development, and regulatory submission. This partnership is designed to support the GPCR research community by expanding access to validated, industry-standard GPCR assay platforms that enable rigorous pharmacological characterization and confident decision-making across the discovery and development continuum. Drawing on more than 25 years of GPCR expertise, Eurofins DiscoverX delivers one of the industry’s most comprehensive GPCR assay portfolios, encompassing over 90% of the human GPCRome with assays for human receptors, species orthologs, and orphan receptors across various cellular backgrounds. Their cell-based assays support a wide range of mechanisms of action, including cAMP accumulation, β-arrestin recruitment, receptor internalization, calcium flux, and ligand binding, generating multidimensional datasets trusted by leading pharmaceutical and biotechnology companies worldwide. Eurofins DiscoverX assay solutions are used throughout GPCR drug discovery workflows, from target identification and validation to high-throughput screening (HTS), lead optimization, safety assessment, and regulatory-compliant potency testing. These assays are widely accepted by industry and regulators and are supported by thousands of peer-reviewed publications and billions of screened data points. “Eurofins DiscoverX is distinguished by its deep GPCR expertise and close collaboration with customers,” said Dr. Yamina Berchiche, Founder and CEO of Dr. GPCR . “They offer more than assays—they build true scientific partnerships that help teams get the most from their data and advance GPCR research with confidence.” “Dr. GPCR plays a critical role in educating and connecting the global GPCR community,” said Geoffrey Donsimoni, GPCR Marketing Director at Eurofins DiscoverX . “Through this collaboration, we look forward to sharing scientific insight, best practices, and real-world applications that help researchers fully leverage GPCR assay technologies across discovery and development.” Together, Dr. GPCR and Eurofins DiscoverX aim to accelerate GPCR-targeted drug discovery by connecting scientists with proven assay platforms, deep pharmacological expertise, and expert-driven context that supports better experimental design and data interpretation. To explore Eurofins DiscoverX GPCR assay solutions and curated resources, visit: https://www.ecosystem.drgpcr.com/eurofins-discoverx To learn more about Dr. GPCR’s educational programs and global GPCR community, visit https://www.ecosystem.drgpcr.com About Dr. GPCR Dr. GPCR is a nonprofit organization connecting the global GPCR community through training, curated news, expert-led courses, and networking. With over 180 podcast episodes , live and on-demand educational programs, and a growing partner ecosystem, Dr. GPCR empowers scientists and organizations advancing GPCR biology and GPCR-targeted drug discovery. About Eurofins DiscoverX Eurofins DiscoverX is a global leader in GPCR cell-based assay technologies, providing industry-standard, regulatory-accepted platforms spanning basic research, drug discovery, and development. With more than 25 years of expertise and coverage of over 90% of the human GPCRome, Eurofins DiscoverX assays are trusted by leading pharmaceutical companies worldwide to generate high-quality, decision-enabling pharmacological data.

🔬Join the #GPCR movement today! ➡️ https://www.ecosystem.drgpcr.com/plans-pricing #gpcr #drgpcr

Boston, MA and Santiago de Compostela, Spain — [June 3rd, 2025]  — Dr. GPCR, the global knowledge hub for G protein-coupled receptor (GPCR) research and education, is proud to welcome Celtarys Research to its partner ecosystem. This collaboration aims to amplify the visibility and adoption of Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics. Celtarys Research develops high-quality, fluorescently labeled ligands and innovative chemical biology tools to support real-time, non-radioactive GPCR assays. These tools enable high-resolution binding studies, kinetic analysis, and live-cell imaging, empowering both academic and industrial scientists to uncover GPCR biology with greater precision and speed. As a Dr. GPCR partner, Celtarys will be featured across multiple touchpoints in the ecosystem, including the Dr. GPCR Newsletter , University Courses , and Podcast , as well as the searchable Dr. GPCR Ecosystem Directory —a centralized hub for tools, training, and technology. “We’re thrilled to partner with Celtarys and introduce their high-performance fluorescent ligands to our global GPCR community,”  said Dr. Yamina Berchiche , Founder and CEO of Dr. GPCR. “These tools can dramatically improve how scientists measure ligand-receptor interactions, visualize binding in live cells, and design better experiments, core to advancing GPCR-targeted discovery.” “Dr. GPCR provides a unique platform to reach scientists at every stage of GPCR research,”  said Wilson Gomes , CEO of Celtarys Research. “This partnership will help accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic breakthroughs.” “We’re excited to support the GPCR community with tools that deliver clarity, sensitivity, and speed,”  added Dr. Maria Majellaro , CSO of Celtarys. “Working with Dr. GPCR allows us to engage with researchers worldwide who are shaping the future of receptor-targeted therapies.” To explore Celtarys Research’s catalog and learn more about their GPCR tools, visit  www.celtarys.com . For access to Dr. GPCR’s global network, educational content, and discovery tools, visit  ecosystem.drgpcr.com . ___________ About Dr. GPCR Dr. GPCR is a nonprofit organization connecting the global GPCR community through training, curated news, expert-led courses, and networking. With over 160 podcast episodes, live and on-demand educational programs, and a dynamic partner ecosystem, Dr. GPCR empowers scientists and companies advancing receptor biology and drug discovery. About Celtarys Research Celtarys Research is a biotech company based in Spain that specializes in the development of optimal chemical tools for drug discovery. Their proprietary chemistry platform enables rapid generation of conjugates, such as labeled ligands, with excellent affinity and pharmacological profiles, designed to advance GPCR-targeted assay development, screening, and live-cell imaging.

Come join us from October 10 to 16 to hear about exciting #GPCR research from amazing speakers.

February 2022 "Switzerland Today, InterAx Biotech is pleased to announce that Carola Weiss has joined

January 2022 "OXFORD, England--Professor Charlotte Deane, Ph.D., of the University of Oxford, has joined Professor Deane joins Exscientia’s technology leadership team, reporting to Chief Technology Officer,

This includes diseases such as depression, Parkinson’s, schizophrenia, and Alzheimer’s. GPR6 has been linked to neuroprotective functions and is now being investigated for its role in Parkinson GPR37 has been linked to the Parkinson’s disease as well, though more focused on the progression of the traditional GPCRs, CBRs are gaining ground as potential therapeutic targets in several CNS diseases, such as Parkinson

Join Dr. Evan O'Brien, PhD, Johns Hopkins University Dr. O'Brien runs a lab at Johns Hopkins that blends cryo-electron microscopy with protein dynamics to build Join Us in Boston Discovery on Target, Boston, MA.

Join Dr. Dopamine D2 receptor modulators  – transforming treatment for Parkinson’s & schizophrenia. discovery or clinical development, the strategies here could open doors in your own therapeutic area. 🧭  Join Let’s move GPCR drug discovery forward — together. 🚨 Mark your calendar for the GPCR Happy Hour Join

John Teye Azietaku for his contributor article on Unveiling GPCR Priming: The Hidden Synergy in Cellular Join us in vibrant Mexico City from October 23 to 25, 2024, for this key event in adhesion GPCR Biology Science Post-Doctoral Fellow—Pharmacology/Cell Biology/Biochemistry Post Doctoral Fellow Postdoc Position Join

As a lab technician at Johns Hopkins, he was fascinated by science but also grounded in real-life responsibilities

His new obsession led him to Johns Hopkins, where he worked in the lab of Dr.

nervous system and neurologic disorders, particularly movement disorders like dyskinesia associated with Parkinson's

Join us for a discussion session on Kumospace, replacing the poster session. cardiometabolic disease GPCRs in Neuroscience Quinpirole ameliorates nigral dopaminergic neuron damage in Parkinson's Christophe Arbet-Engels to Join as Chief Medical Officer GPCR Events, Meetings, and Webinars ONCORNET2.0

the G protein-coupled A2A adenosine receptor (A2AAR) have been considered promising agents to treat Parkinson's

neuropsychiatric diseases including Amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, Parkinson's

Continue to increase your knowledge of Pharmacology by joining this practical approach class today. GPCR Partnered Events April 22 - 23, 2024 | Endocrine Metabolic GPCRs Join the Endocrine Metabolic GPCRs bioinformatics analysis Unveiling the therapeutic prospects of EGFR inhibition in rotenone-mediated parkinsonism Feeding Behavior Director of Laboratory Operations - Single-molecule Imaging Center Scientific Assistant Join

This Week’s Highlights: Congrats to: John Teye Azietaku , our great contributor, for his article Class

GPCR University February 8 - 29: Join Dr. GPCR University's live course with Dr. Terry Kenakin. April 22 - 23, 2024 | Endocrine Metabolic GPCRs Join us at the Endocrine Metabolic GPCRs event on April MolFlux: Empowering the ML Community in Molecular Predictive Modelling NanoImaging Services Appoints John

rat retrosplenial cortex Unveiling the therapeutic prospects of EGFR inhibition in rotenone-mediated parkinsonism GPCR Drug Discovery Biologist Post-Doctoral Scientist- Molecular Pharmacology (FDE) Research Assistant Join

Molecular determinants of ligand efficacy and potency in GPCR signaling Save the date: February 8 - 29: Join application of optogenetically functionalized Drosophila dopamine receptors Targeting CB2R in astrocytes for Parkinson's

Save the date: February 8 - 29: Join Dr. GPCR University's live Zoom sessions hosted by Dr. Meaningful Proof-of-Concept Data From Phase 2a Clinical Study Neurocrine opening two Phase 1 trials in oral Parkinson

and D1R antagonism, kurarinone might be a potential compound that can alleviate clinical symptoms of Parkinson's

It is involved in several pathophysiological processes such as Parkinson’s disease, depression, addiction Cannabinoid Receptor Type 1 in Parkinson’s Disease: A Positron Emission Tomography Study with [ 18 F   A.; Bohn, L. M.; Makriyannis, A.; Stevens, R. C.; Liu, Z.-J. J.; Wang, J.; Wu, M.; Katritch, V.; Zhao, S.; Kunos, G.; Bohn, L. M.; Makriyannis, A.; Stevens, R.

beneficial pharmacological effects in the treatment of several neurological disorders including, epilepsy, Parkinson